Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hengrui Pharmaceuticals makes and sells prescription drugs — mainly cancer medicines, anesthetics, heart drugs, and anti-infectives — to hospitals and patients in China and around the world.
Hengrui Pharmaceuticals is one of China's biggest makers of prescription medicines. It sells drugs that treat cancer, drugs that put patients to sleep or kill pain before surgery, heart and blood pressure medicines, and anti-infection drugs. Its customers are mostly hospitals and doctors, who choose its products because they work and because the company sells them at prices Chinese patients and insurers can actually pay.
The cancer business is the engine. Hengrui was early to build a large pipeline of its own oncology drugs rather than just copying medicines other companies invented, and that bet made it a leader in China. The anesthetics side is quieter but dependable: every surgery needs them, and hospitals stick with brands they trust. The company spends heavily on research — one of the largest drug research budgets of any Chinese pharma firm — because in drugs, whoever invents the next good medicine wins. The business is changing shape. China's government-run insurance fund has been squeezing drug prices hard in recent years, especially for older medicines, which pressured growth. Hengrui's answer is to invent more genuinely new drugs and sell them abroad. It has struck licensing deals with foreign drugmakers who pay it upfront and then take its experimental medicines through global trials, giving Hengrui global reach without building its own sales force in every country.
Hengrui's home base is Lianyungang, a port city in Jiangsu province, and it has been listed on the Shanghai Stock Exchange since 2000. It pays a dividend and has generally kept a strong balance sheet, which matters in a business where a single failed late-stage trial can waste years and huge sums. The big question hanging over it is simple: can a Chinese company that got big selling affordable drugs at home become a global innovator whose new medicines earn rich prices in the United States and Europe?
Saved answer · last researched 12 Nov 2026